Wednesday, May 8, 2024 5/8/2024

Systematic study of variations in imaging techniques and response criteria for well differentiated pancreatic neuroendocrine tumors

Award Number: R03CA219722
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY/ABSTRACT: Neuroendocrine tumors (NETs) are rare and slow growing malignancies with an increasing incidence and prevalence1. The relevance of current standard imaging modalities and response assessment criteria (RECIST 1.1) is questioned for evaluation of NETs due to inter-observer variability and the inability to evaluate early response to therapy (changes in vascularity, textures, density)4. Ours is a unique pilot project where we utilize and repurpose an untapped resource i.e., image bank created from the cooperative group study E2211 that randomized patients with pancreatic NETs to capecitabine +/- temozolamide therapy. We will review all of the images available in the image bank and perform secondary analysis to quantify variability in both: imaging technique/radiation dose (discrepancies in image quality) and tumor measurements using RECIST 1.1 (response criteria). These findings are vital to disease evaluation in NETs. Alongside, we also hypothesize that there are alternate criteria (RECIST lite, Choi, changes in texture, intensity and other quantitative imaging markers) that could evaluate response to therapy on CT imaging better and earlier than the current standard (RECIST 1.1) as previously shown in gastrointestinal stromal tumors (Choi criteria)5,6. The feasibility of image banking and its utility in answering clinically relevant questions is also being indirectly evaluated through our study. Assessing the quality of imaging studies and quantifying the inter-reader variability will highlight the importance of standardizing disease assessment tools and justify the need for exploring alternate tools. Identification of alternate radiological criteria and quantitative imaging biomarkers that are early predictors of response will help us identify patients who are more likely to respond to any specific therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	THE INSTITUTE FOR CANCER RESEARCH	333 COTTMAN AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	2	10/13/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $92,150 )
2021	2021	INSTITUTE FOR CANCER RESEARCH, THE	333 COTTMAN AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	2	12/15/2020	NON-COMPETING CONTINUATION	$92,150
														Subtotal = $92,150

Issue Date FY: 2020 ( Subtotal = $92,150 )
2020	2020	INSTITUTE FOR CANCER RESEARCH, THE	333 COTTMAN AVE	PHILADELPHIA	PA	19111	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	1	12/23/2019	NEW	$92,150
														Subtotal = $92,150

Grand Total All Awards = $184,300

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Systematic study of variations in imaging techniques and response criteria for well differentiated pancreatic neuroendocrine tumors

Award Number: R03CA219722

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer